Marker Therapeutics Inc. (MRKR) stock Bullish After Hours on News of FDA Designation
On January 19, Marker Therapeutics Inc. (MRKR) announced FDA Orphan Drug designation for its pancreatic cancer T-cell therapy. Following the announcement, the stock became bullish